Andere talen Veru Inc.

Aandelen

VERU

US92536C1036

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 25-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,7946 ^USD	-6,67%		-1,06%	+10,36%

22/05	Veru Inc. presenteert op de Jefferies Global Healthcare Conference een update van Veru's Fase 2B klinische programma van enobosarm om vetverlies te bevorderen en spierverlies te voorkomen in combinatie met GLP-1-medicijnen voor gewichtsverlies	CI
14/05	VERU INC. : B. Riley herhaalt koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions	24/06
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024	18/06
Veru Reminds Shareholders to Vote in Advance of tomorrow s Deadline for 2024 Annual Meeting of Shareholders	18/06
Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Shareholders	17/06
Veru to Present at the American Diabetes Association's 84th Scientific Sessions	10/06
Veru to Present at the Jefferies Global Healthcare Conference	22/05
Veru Inc. to Present an Update of Veru's Phase 2B Clinical Program of Enobosarm to Augment Fat Loss and to Avoid Muscle Loss When Combined with GLP-1 Drugs for Weight Loss At the Jefferies Global Healthcare Conference	22/05
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss	15/05
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week	14/05
Veru Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	08/05
Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M	08/05
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program	08/05
Veru to Present at the GLP-1 Based Therapeutics Summit	02/05
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024	01/05
Veru : Corporate Presentation, May 2024	30/04
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	30/04
Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	30/04
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11	25/04
Veru Announces Date of 2024 Annual Meeting of Shareholders	01/04
Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	01/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Veru Inc.

Aandelen

VERU

US92536C1036

Andere talen

Filters